Success Story: Advancing Precision Cancer Treatment Through Nanomedicine: NIW Approval Secured for a Pharmaceutics Researcher

Client’s Testimonial:

 

“Thank you very much for your support and guidance throughout my EB-2 NIW petition. I truly appreciate your help in achieving this important milestone.”

 


 

On October 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Scholar in the Field of Cancer Nanomedicine (Approval Notice).

 


 

General Field: Cancer Nanomedicine 

 

Position at the Time of Case Filing: Postdoctoral Scholar

 

Country of Origin: Nepal

 

State of Residence at the Time of Filing: California

 

Approval Notice Date: October 8th, 2026

 

Processing Time: 2 months, 2 days (Premium Processing Requested)

 


 

Case Summary:

 

Advancing cancer treatment requires innovative approaches that can improve drug delivery, increase treatment precision, and address resistance to existing therapies. Working in the field of Cancer Nanomedicine, the client, who holds a Ph.D. in Pharmaceutics and is currently conducting research at a U.S. university, sought an EB-2 National Interest Waiver (NIW) to continue contributing to this important area of medical research. The client's proposed endeavor focuses on developing advanced therapeutic delivery systems to improve the effectiveness of cancer treatments, particularly for aggressive and drug-resistant tumors.


We presented the client's research as an endeavor of substantial merit and national importance by emphasizing its potential to address significant challenges in cancer care. The petition connected the client's work in targeted drug delivery and precision medicine to broader U.S. healthcare priorities, including improving treatment outcomes, addressing drug resistance, and reducing the burden associated with cancer. We further demonstrated that the potential benefits of this research extend beyond a single institution, supporting continued advancements in cancer treatment and biomedical innovation.


To establish that the client was well positioned to advance the proposed endeavor, we highlighted an extensive record of scholarly contributions and professional recognition, including 71 peer-reviewed journal articles, 13 book chapters, 5 granted patents, 2,243 citations, and at least 40 completed peer reviews. These achievements reflected the client's sustained involvement in pharmaceutical and biomedical research. The petition also emphasized the client's editorial responsibilities and experience in developing advanced drug delivery technologies as additional evidence of specialized expertise.


Beyond presenting these credentials, our legal team demonstrated the broader significance of the client's research through objective evidence of its influence on other researchers. We highlighted how independent scientists had drawn upon the client's findings to develop and evaluate new therapeutic delivery systems, improve drug targeting, and investigate the safety and effectiveness of emerging biomedical technologies. The petition also incorporated comparative citation evidence showing that several of the client's publications ranked among the most frequently cited works in their respective publication years. Together, these examples helped establish that the client's contributions had informed further scientific investigations and provided a foundation for continued progress in the field.


The client's I-140 NIW petition was approved with direct premium processing, allowing the client to continue pursuing research aimed at improving precision cancer therapies. This case illustrates how a well-documented combination of advanced education, scholarly influence, independent research recognition, and a clearly defined proposed endeavor can support NIW eligibility under the Matter of Dhanasar framework.